Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 5/20 | 0.55 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.52 |
| ▸ | CNR1 | P21554 | 3/20 | 0.49 |
| ▸ | CNR2 | P34972 | 2/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13802434 | 0.96 | PTGDR2 (0.53) | PLA2G2APTGDR2CNR1CNR2THRA | |
| SCHEMBL13802426 | 0.94 | PTGDR2 (0.55) | PLA2G2APTGDR2THRATHRBABCB1 | |
| SCHEMBL7952544 | 0.82 | PLA2G2A (0.82) | PLA2G2APTGDR2KDM4EABCB1PTGS1 | |
| SCHEMBL18294853 | 0.79 | PLA2G2A (0.50) | PLA2G2ACNR1CNR2NPC1 | |
| SCHEMBL18294880 | 0.78 | PLA2G2A (0.48) | PLA2G2ACNR1CNR2NPC1 | |
| SCHEMBL13802385 | 0.78 | ABCB1 (0.55) | PLA2G2APTGDR2KDM4ESMN1; SMN2ABCB1 | |
| SCHEMBL18294883 | 0.76 | PTGER4 (0.47) | PLA2G2ACNR2NPC1 | |
| SCHEMBL13802437 | 0.76 | ABCB1 (0.56) | PLA2G2APTGDR2ABCB1PTGS1PTGS2 | |
| SCHEMBL7140681 | 0.74 | NPC1 (0.53) | CNR1CNR2KDM4ENPC1 | |
| SCHEMBL18294839 | 0.74 | PLA2G2A (0.45) | PLA2G2APTGDR2CNR1CNR2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | PLA2G2A 409/4885PTGDR2 2287/4885CNR1 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.